Evaluation of the Effectiveness of Carvedilol in the Treatment of Patients with Chronic Heart Failure

Abstract

The study aimed to determine the clinical efficacy and safety of carvedilol in patients with chronic heart failure. 50 patients with chronic heart failure (CHF) of functional class II-III (FC) and left ventricular ejection fraction (LV) of less than 45% were examined. All patients, in addition to ACE inhibitors, were prescribed carvedilol at an initial daily dose of 6.25 mg with the possibility of increasing the dose to 50 mg per day, divided into two doses. The duration of follow-up was 6 months. To determine the effectiveness of carvedilol treatment, at the beginning of the study and after 6 months of treatment, the clinical condition of patients with CHF was assessed (Mareeva V.Yu. scale, 2000), the distance of a six-minute walk and the functional class of CHF were determined, echocardiographic examination was performed and Dopplerography of the brachial artery and the humoral marker Willebrand factor were performed to assess the function of the endothelium. The inclusion of carvedilol in the treatment regimen of patients with CHF was accompanied by an improvement in the clinical condition of patients and an increase in exercise tolerance. The use of carvedilol in combination with standard therapy of patients with CHF not only improves the structural and geometric parameters of LV, improves LV systolic function and functional activity of patients, but also improves the functional state of the endothelium.